Collateral for a security interest recorded Jul 13, 2026 (Biopharma Credit PLC).
Term ends Mar 14, 2036 · High confidence
20-year base term ends Mar 14, 2036
Held by Esperion Therapeutics, Inc.
Filed Dec 29, 2020 as application 17/136,870 · Granted Sep 5, 2023
Base term, 20 years from filing
Today
2016
2036
Clock starts
Mar 14, 2016
Mar 14, 2016
Term ends
Mar 14, 2036
Mar 14, 2036
Granted
Sep 5, 2023
Sep 5, 2023
base term
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,912,751, to Mar 14, 2036. The term already ends on or before that date, so the cap shortened nothing.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 0 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 14, 2016, when application PCT/US2016/022319, the earliest non-provisional in its chain, was filed (this one was filed Dec 29, 2020) | Mar 14, 2036 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,912,751) | resolves to Mar 14, 2036, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Mar 14, 2036 | High confidence |
This family
| Application PCT/US2016/022319 | PCT application no patent term | no patent term |
| US 10,912,751 | In force Mar 2036 | Mar 2036 |
| US 11,744,816 | this patent Mar 2036 | Mar 2036 |
| Application 18/351,958 | Abandoned not computed | not computed |
| Application 18/601,088 | Pending not computed | not computed |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 30, 2023 Reel 64129, frame 705 | Newton, Roger Schofield; Rosenberg, Noah Laban; Macdougall, Diane Elaine | Esperion Therapeutics, Inc. | Assignment of Assignor's Interest |
| Jun 27, 2024 Reel 67963, frame 94 | Eiger III S.A. LLC | Esperion Therapeutics, Inc. | Release of Security Interest |
| Dec 13, 2024 Reel 69582, frame 756 | Esperion Therapeutics, Inc. | Glas Americas LLC | Security Interest |
| Jul 13, 2026 Reel 75952, frame 812 | Esperion Therapeutics, Inc.; Resq Pharmaceuticals LLC | Biopharma Credit PLC, as Collateral Agent | Patent Security Agreement |
| Jul 14, 2026 Reel 75267, frame 816 | Glas Americas LLC | Esperion Therapeutics Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Mar 2036
Term ends Mar 14, 2036. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,912,751, ends no earlier than this term, so it caps nothing.
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.